Mode
Text Size
Log in / Sign up

Megestrol acetate 320 mg/day improved nutritional indices and reduced fatigue in cancer cachexia patients compared to diet aloneMegestrol Acetate Helps Cancer Patients Keep Weight and Muscle

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider megestrol acetate 320 mg/day for cancer cachexia; it improved nutritional indices and fatigue in this quasi-experimental study.

This prospective quasi-experimental study enrolled 97 patients with cancer cachexia. The intervention group received regular diet plus megestrol acetate (MA) 320 mg/day, while the comparator group received regular diet alone. The follow-up period was 2 months. No reported drug-related adverse events or discontinuations were observed, indicating the regimen was well-tolerated in this cohort.

Regarding primary outcomes, the MA group demonstrated significant improvements in body weight, BMI, fat mass, prealbumin, albumin, and hemoglobin compared to baseline. These improvements were significantly greater in the MA group compared to the control group. Skeletal muscle mass was maintained in the MA group, whereas the control group experienced significant loss, resulting in a significant between-group difference.

For secondary outcomes, the MA group showed significant reduction in IL-6 levels compared to baseline and markedly greater reductions compared to the control group. Cancer-related fatigue across all domains decreased significantly in the MA group compared to baseline, with reductions markedly greater than in the control group. Quality of life showed more substantial improvement in the MA group compared to the control group. Conversely, most inflammatory or immune markers, including CD4+ and CD8+ T cells, showed no significant between-group differences.

The study design is a prospective quasi-experimental study, which precludes definitive causal conclusions. As the study phase, publication type, setting, and funding sources were not reported, the generalizability of these findings remains uncertain. Clinicians should interpret these results with caution regarding the specific efficacy of MA for cancer cachexia.

A new study shows a common drug may do more than just boost appetite in wasting syndrome.

A Silent Struggle at the Dinner Table

Imagine sitting down to a meal you once enjoyed, but now the thought of eating feels like a chore. You’re losing weight without trying, and your clothes hang loose. This is the daily reality for many cancer patients facing cachexia.

It’s more than just being thin. It’s a wasting syndrome that steals muscle, energy, and hope. Now, a new study suggests a common medication might help turn the tide.

Cancer cachexia is a serious problem. It affects up to 80% of cancer patients and is a major cause of death and poor quality of life. It’s not just about losing fat; it’s about losing vital muscle that helps you move and breathe.

Current treatments are limited. Doctors often recommend high-calorie drinks, but these don’t always stop muscle loss. Patients feel exhausted, weak, and depressed. Families watch their loved ones fade, feeling helpless.

This study looks at megestrol acetate (MA), a drug already used to stimulate appetite. But the question was: does it do more than just make people eat?

For years, the main goal in cachexia was simple: gain weight. Doctors used drugs like megestrol acetate to boost appetite and calorie intake. The focus was on the number on the scale.

But here’s the twist. Gaining weight isn’t enough if you’re losing muscle. A patient could gain fat but still become weaker. This study shifts the focus from just weight to body composition—what kind of weight is being gained.

The new research suggests megestrol acetate might help preserve muscle while increasing fat and improving overall health markers.

How It Works: The Body’s Balance Switch

Think of your body’s metabolism like a seesaw. In cancer cachexia, the seesaw is stuck in a bad position: it’s breaking down muscle for energy faster than it can build it back up.

Megestrol acetate is like a gentle hand pushing the seesaw back to balance. It’s a synthetic hormone that works by affecting the body’s hunger signals and energy use.

Here’s a simple analogy: Imagine your body is a factory. In cachexia, the factory is in overdrive, taking apart its own machinery (muscle) to make fuel. MA acts like a manager who says, “Slow down. Let’s use the raw materials we’re getting from food instead.” This helps the body store more energy and protect its muscle machinery.

A Look at the Study

Researchers in China conducted a prospective study with 97 cancer patients suffering from cachexia. They were not randomly assigned, which is a limitation.

For two months, one group (33 patients) continued their regular diet. The other group (64 patients) took megestrol acetate (320 mg daily) along with their regular diet.

Scientists measured weight, body mass index (BMI), muscle and fat mass, blood markers for inflammation and nutrition, fatigue levels, and quality of life.

What They Found: More Than Just Weight Gain

The results were clear. Compared to their own starting point, patients taking megestrol acetate saw significant improvements.

They gained weight and BMI. More importantly, they gained fat mass and maintained their skeletal muscle mass. In contrast, the control group lost significant muscle.

Their blood work improved too. Levels of prealbumin, albumin, and hemoglobin—all key markers of nutrition and health—went up. A key inflammatory marker, IL-6, also dropped.

But the most meaningful changes were in how patients felt. The MA group reported a major reduction in cancer-related fatigue across all domains: physical, cognitive, and emotional. Their overall quality of life scores also improved significantly.

When comparing the two groups, the MA group did better in almost every area: weight, BMI, fat mass, muscle preservation, nutrition markers, fatigue, and quality of life.

This doesn’t mean this treatment is available yet.

While the study is promising, it’s important to see it in context. The findings align with the growing understanding that cachexia treatment needs to be multi-dimensional. It’s not just about calories; it’s about protecting muscle and improving how a patient feels day-to-day. This study adds robust evidence that megestrol acetate can be a valuable tool in this fight.

If you or a loved one is dealing with cancer cachexia, this is hopeful news. Megestrol acetate is an existing, well-tolerated drug. However, this study does not mean you should start taking it on your own.

Always talk to your doctor. They can determine if this medication is appropriate for your specific situation, considering your cancer type, treatment plan, and overall health.

This study is a step forward, but it’s not the final word. The research was non-randomized and relatively small. The next steps would be larger, randomized controlled trials to confirm these findings.

Researchers will also need to look at long-term effects and see if the benefits hold up over time. For now, this study gives doctors and patients a stronger reason to consider megestrol acetate as part of a comprehensive plan to manage cancer cachexia.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe objective of this study is to investigate the efficacy of megestrol acetate (MA) in treating cancer cachexia from multiple dimensions.MethodsIn this prospective, non-randomized study, 97 patients with cancer cachexia were allocated to either a control group (n = 33, regular diet) or an MA group (n = 64, regular diet plus MA 320 mg/day) for 2 months. The primary endpoints were nutritional indices, including weight, BMI, total skeletal muscle mass, and fat mass. Secondary endpoints included inflammatory markers (CRP, IL-6, TNF-α), immune parameters (CD4+, CD8+ T cells), cancer-related fatigue (assessed by the Cancer Fatigue Scale), and quality of life (QOL).ResultsCompared to baseline, the MA group exhibited significant improvements in body weight, BMI, fat mass, prealbumin (PA), albumin (ALB), and hemoglobin (Hb), coupled with a significant reduction in IL-6 levels and all domains of cancer-related fatigue (somatic, cognitive, affective, and total). Between-group analyses demonstrated that the MA group achieved significantly greater improvements in weight, BMI, fat mass, PA, ALB, and Hb. Skeletal muscle mass was maintained in the MA group, whereas the control group experienced a significant loss, resulting in a significant between-group difference. Furthermore, the MA group showed markedly greater reductions in all fatigue domain scores and a more substantial improvement in QOL. No significant between-group differences were observed for most inflammatory or immune markers. The intervention was well-tolerated with no reported drug-related adverse events.ConclusionMA significantly improves nutritional status and ameliorates cancer-related fatigue, thereby enhancing the quality of life in patients with cancer cachexia. Our findings provide robust evidence supporting the multi-dimensional benefits of MA in cachexia management, extending beyond mere weight gain to include muscle mass preservation and patient-centered symptom relief.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.